Pentoxifylline reduces pulmonary leucostasis and improves capillary patency in a rabbit peritonitis model.
This study examines the changes in pulmonary leucostasis and capillary ultrastructure in 18 rabbits divided into three groups. Those in the first group were sham operated, and those in the second and third groups underwent peritonitis induction; those in the latter group were treated with pentoxifylline (PTF). White blood cells (WBC) were counted, and tissue area, total capillary area, and capillary patency were measured from electron micrographs of lung tissue. Pulmonary WBCs were 1.2 per unit field in the sham group, 9.7 in the test group (P less than 0.001 compared with sham), and 2.5 in the PTF group (P less than 0.001 compared with sham). Capillary patency was 53 +/- 5% in the sham group, 12 +/- 4% (P less than 0.001 compared with sham) in the test group, and 24 +/- 2% (P less than 0.001 compared with sham) in the PTF group. Pentoxifylline treatment attenuates pulmonary leucostasis, pulmonary capillary occlusion, and endothelial and epithelial damage associated with peritonitis in rabbits. This study shows that PTF warrants investigation into its potential protective effects on the lungs in clinical sepsis.
Tighe
D
D
Department of Medicine 1, St. George's Hospital Medical School, London, England.
Moss
R
R
Heath
M F
MF
Hynd
J
J
Bennett
E D
ED
D000818:Animals; D002196:Capillaries / Q000473:pathology; D004727:Endothelium / Q000473:pathology; D004848:Epithelium / Q000473:pathology; D007962:Leukocytes / Q000473:pathology*; D008168:Lung / Q000098:blood supply / Q000473:pathology*; D008854:Microscopy, Electron; D010431:Pentoxifylline / Q000627:therapeutic use*; D010538:Peritonitis / Q000188:drug therapy / Q000473:pathology*; D011817:Rabbits; D013805:Theobromine / Q000031:analogs & derivatives*; D014654:Vascular Patency
D013805:Theobromine; D010431:Pentoxifylline